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Abstract: Astrocytes perform a wide variety of essential functions defining normal operation of the
nervous system and are active contributors to the pathogenesis of neurodegenerative disorders such
as Alzheimer’s among others. Recent data provide compelling evidence that distinct astrocyte states
are associated with specific stages of Alzheimer´s disease. The advent of transcriptomics technologies
enables rapid progress in the characterisation of such pathological astrocyte states. In this review,
we provide an overview of the origin, main functions, molecular and morphological features of
astrocytes in physiological as well as pathological conditions related to Alzheimer´s disease. We will
also explore the main roles of astrocytes in the pathogenesis of Alzheimer´s disease and summarize
main transcriptional changes and altered molecular pathways observed in astrocytes during the
course of the disease.
Keywords: astrocyte; Alzheimer´s disease; neurodegeneration; transcriptomics; RNA sequencing
(RNA-seq); cellular states
1. Introduction
In 1856, Rudolf Virchow introduced the concept of neuroglia as a connective tissue
of the brain and the spinal cord that holds together nervous elements [1]. Glial cells
have been in focus of research of many prominent neuroanatomists of the 19th century;
in particular morphology of parenchymal glia characterized by stellate appearance when
stained by Golgi technique has been minutely characterised [2]. These stellate cells received
the name of astrocytes (αστρoνκψτoσ; astron, star and kytos, a hollow vessel, later cell i.e.,
star-like cell) [3]. Rather prophetically, Lenhossék proposed to call all parenchymal glial
cells “spongiocytes” and he only named a subpopulation of them as astrocytes. Astrocytes
belong to the class of neural cells known as astroglia, which covers several different cell
types including astrocytes proper, radial astrocytes, velate astrocytes, tanycytes, pituicytes,
ependymocytes, choroid plexus cells and retinal pigment epithelial cells. Astrocytes are
parenchymal homeostatic and defensive cells of the central nervous system (CNS). Re-
cent data provide clear evidence that astrocytes actively contribute to the pathogenesis
of neurodegenerative disorders, with particular role in Alzheimer’s disease, Parkinson
disease, Huntington disease, multiple sclerosis and amyotrophic lateral sclerosis. In this
review, we provide overview of the multifaceted roles of astrocytes in physiological as
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well as pathological conditions related to Alzheimer´s disease. We also explore mecha-
nisms by which astrocytes contribute to Alzheimer´s and summarize main transcriptional
changes and altered molecular pathways observed in astrocytes during the course of
Alzheimer´s disease.
2. Astrocytes in the Healthy Brain
2.1. Origin, Development and Numbers
2.1.1. Origin
Astrocytes, similar to neurones and oligodendroglia, originate from neuroepithelium-
derived radial glial cells. At prenatal stages, astroglial precursors are produced by asym-
metric division of radial glial cells. The bulk of astrocytes however emerges postnatally and
the major source for astrogenesis is associated with symmetric division of differentiated as-
trocytes; this division was initially described by Ramon y Cajal in a form of twin astrocytes
or “astrocitos gemelos” [4]. Astrocytes can also emerge from direct transformation of radial
glia or differentiate from NG2 glial cells also known as oligodendrocyte precursors or OPCs
(Figure 1A) [5,6]. Intermediate glial progenitor cells, originated from asymmetric division
of radial glia, generate immature astrocytes that migrate towards the cortical layers and
proliferate through symmetric division. In layer I of the embryonic and neonatal cortex
there are other type of neural progenitors that give rise to the astrocytes of superficial layers
(I–IV) (Figure 1A) [7].
2.1.2. Prenatal Astrogenesis
In foetal brain development, gliogenesis follows neurogenesis. Molecular mechanisms
that govern differentiation of astrocytes are mainly determined by the expression of two
astrocytic genes: intermediate filament glial fibrillary acidic protein (GFAP) and calcium
binding protein (S100β) [8,9]. Three signalling pathways, JAK-STAT, Notch and BMP-
SMAD, determine the embryonic development of astrocytes. The IL-6 family of cytokines
(CNTF, LIF, CT-1) are primarily responsible for initiating gliogenesis [10]. This family acti-
vates the canonical JAK/STAT signalling pathway; activated STAT is responsible, together
with the p300/CBP co-activator complex, for promoting transcription of astroglial genes
to instigate formation of astrocytes [9,11–13] (Figure 1B). In the course of astrogenesis,
JAK/STAT and Notch signalling pathways act synergistically: activation of JAK produces
the release of Notch ligands to activate this pathway; Notch activity, on the other hand,
induces the phosphorylation of STAT thus activating JAK/STAT cascade [12] (Figure 1B).
Notch is also involved in the demethylation and, therefore, in epigenetic regulation of
astrocytic genes during differentiation. In neurogenesis, the promoter of the astrocytic
gene glial fibrillary acidic protein (GFAP) is epigenetically silenced through methylation
by DNA methyltransferase I (DNMT1). When astrogenesis begins, Notch signalling path-
way activates DNMT1 release, allowing GFAP transcription and astrogenesis. Epigenetic
regulation of astrocytic genes is also regulated by JAK/STAT pathway since acetylation of
histones by p300/CBP enhances the opening of chromatin [12]. Notch cascade also pro-
motes astrogenesis by directly activating the GFAP promoter [8]. In addition, BMP ligands,
members of the transforming growth factor beta (TGF-β) signalling ligands superfamily,
bind to and activate their respective receptors inducing SMAD phosphorylation and its
dimerisation with SMAD4. The SMAD-SMAD4 complex is a transcriptional activator of
astrocytic genes such as GFAP and calcium-binding protein β (S100β) which promote astro-
genesis (Figure 1B). This astrogenesis signalling pathway has been described in progenitor
cultures at embryonic day 14 and later; besides promoting astrogenesis this pathway
suppresses neuronal and oligodendrocytic differentiation [10,14–16]. Both JAK-STAT and
Notch pathways are also activated by BMP signalling [10,17].
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Figure 1. Origin and development of human astrocytes in the healthy brain. (A) Astrocytes originate
at pre- and post-natal stages by symmetric or asymmetric division as well as by direct transformation
of radial glia, intermediate glial progenitors, already differentiated astrocytes and NG2 glia. (B) Three
signalling pathways determine astrocytic development: the JAK/STAT (Janus Kinases and signal
transducer and activator of transcription proteins), NOTCH (Notch homolog 1) and BMP-SMAD
(Bone Morphogenetic Proteins and “Small Mothers Against Decapentaplegic”). These pathways act
synergistically allowing the transcription of astroglial genes. MZ: marginal zone, MA: mantle, SVZ:
subventricular zone, VZ: ventricular zone.
2.1.3. Postnatal Astrogenesis
The second, and the largest wave of astrogenesis occurs postnatally. During postnatal
astrogenesis, approximately 50% of all astrocytes are generated from the symmetric division
of differentiated astrocytes [18] (Figure 1A). In this second wave, protoplasmic astrocytes
are also generated by direct transformation of radial glia, which lose their apical processes;
besides, astrocytes can arise from NG2 glial cells [19–21] (Figure 1A). The importance of the
BMP-SMAD signalling pathway in adult astrogenesis is well documented: inactivation of
this pathway reduces the expression of astrocytic genes such as GFAP and S100β, and de-
creases the number of astrocytes [16]. In contrast, the number of GFAP-positive astrocytes
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increases substantially in a mouse model overexpressing BMP [22]. More studies are
needed to elucidate other potential signalling cascades involved in postnatal astrogenesis.
2.1.4. Astrocyte Numbers
There is some controversy about the total number of astrocytes, and their proportion
in different brain regions remains to be elucidated. Isotropic fractionation and quantitative
unbiased stereology estimate that all glia accounts for ~40% of all cells in the human brain;
the ratio of non-neuronal cells to neurones varies depending on the region [23–25] being
0.2:1 in the cerebellum, 3.7:1 in the cortex and up 7:1 in the spinal cord and 11:1 in the
brain stem [7].
In different brain regions astrocytes account for 20–40% of the total glial population,
suggesting that oligodendrocytes are slightly more numerous [7,23]. Stereology studies
(without immunocytochemistry) on post-mortem human brain samples report 75% oligo-
dendrocytes, 20% astrocytes and 5% microglia in neocortex [26]. In mouse cortex the ratio
of astrocytes to neurones is around 0.2 [27].
2.2. Astrocyte Functions in Healthy Brain
Astrocytes perform a wide variety of critical functions determining normal operation
of the nervous tissue. Numerous receptors expressed in astrocytes allow them to sense neu-
ronal activity [28], activation of these receptors trigger astrocytic ionic signalling, mainly
mediated by changes in cytosolic concentration of Ca2+ and Na+ [29] which control a mul-
titude of plasmalemmal “homeostatic” transporters [30]. In addition, astrocytic excitability
is supported by second messengers such as ATP [31]. These transporters are responsible
for K+ buffering, clearance of neurotransmitters including glutamate, ATP, GABA, adeno-
sine and endocannabinoids among others, maintaining synaptic transmission, preventing
excitotoxicity and providing for neuroprotection [7,32]. These transporters specifically
concentrate in distal astroglial processes that enwrap synaptic contacts; the perisynaptic
membranous sheath form the astroglial cradle, essential for all aspects of synaptic function
from synaptogenesis and synaptic maintenance to synaptic extinction [33]. Astrocytes
promote synaptogenesis by producing and secreting critically important factors such as
cholesterol, glypicans, hevin and thrombospondins [34,35]. They also control synapse
elimination by direct phagocytosis [36] or by modulating microglia synaptic pruning in a
complement dependent process [37]. Astrocytic endfeet contact blood vessels and, together
with endothelial cells and pericytes, create the blood-brain barrier (BBB) which separates
the highly controlled brain microenvironment from the peripheral blood circulation [38].
Astrocytes form a functional and anatomical link between the vasculature and the CNS
parenchyma through the neurogliovascular unit [39], regulate local blood flow and contribute
to energy supply in the form of lactate to neurones [40,41]. They store glycogen, which is
metabolised to pyruvate and lactate, with the latter transported across the cell membrane
and delivered to neighbouring neurones. Astrocytes are fundamental for operation of the
glymphatic system, an organised pathway for elimination of soluble proteins, waste products,
and excess extracellular fluid from the brain, in which clearance is facilitated by astrocytic
aquaporin 4 (AQP4) water channels [42,43]. Finally, they control extracellular space volume
and are also in charge of the homeostatic maintenance of the CNS by transporting extracellular
ions, protons and metabolites, and controlling levels of pH and water [7].
2.3. Astrocyte Diversity
Although belonging to the same class of neural cells and sharing same basic prop-
erties (such as high K+ permeability, expression of transporters providing for molecular
homeostasis, ionic excitability, etcetera) [7], there is a prominent inter- and intra-regional
heterogeneity among astrocytic populations at both morphological and molecular levels,
which translates into differential functional properties. Heterogeneity of astrocytes might
be explained, at least in part, by their diverse place of birth and association to specific type
Cells 2021, 10, 540 5 of 19
of progenitors. Intrinsic programs within the astrocytic precursors and extrinsic signals
from neighbouring cells can also influence the diversity.
2.3.1. Morphological Subtypes of Cortical Astrocytes: Protoplasmic, Interlaminar,
Varicose-Projection and Fibrous Astrocytes
There are four main morphologically distinct subtypes of astrocytes in the human
neocortex while only two have been found in rodents:
Protoplasmic astrocytes represent the most abundant type of astroglia in the grey matter
and are located in cortical layers II to VI [44]. They are characterised by a small cell
body, of approx. 10 µm in diameter with many large processes (up to 40 in humans,
several in rodents). These processes extend radially from the soma, and many complex
and fine lateral branches are born from them, defining the territory of astrocyte domain.
Territorial domains of cortical protoplasmic astrocytes show very little (<5%) overlap [45].
The volume of human protoplasmic astrocytes is about 10 to 20 times greater than that of
rodent astrocytes [46].
Interlaminar astrocytes are almost exclusively found in higher primates (the processes
of the so called "rudimentary interlaminar astrocytes" described in mouse [47] do not
cross the Lamina 1 and hence cannot be defined as interlaminar), and emerge at postnatal
stages. Their somata are located in layer I of the cerebral cortex. These cell bodies are
around 10 µm diameter; and several generally unbranched processes emanate from them.
These processes are of two types: shorter fibres directed towards the cortex surface that
contribute to the astrocytic network underneath the pia mater, and very long fibres that
penetrate through the deep layers of the cortex (layers III–IV). Interlaminar astrocytes do
not occupy specific territorial domains and overlap with their neighbours. They express
markers of radial glia (Pax6, Sox2, and Nestin), as well as astrocytic markers GFAP, S100β,
Aqp4, and GLAST [47]. Grafting human iPSC-derived astrocyte progenitors in the mouse
brain results in appearance of GFAP-positive interlaminar astrocytes in layer I of the
mouse cortex (Figure 2A). Although functions of interlaminar astrocytes remain enigmatic,
their structure suggests an essential role in intra-cortical communication [44,46,48,49].
Varicose-projection astrocytes are similarly found only in primate brains. These cells are
located in cortical layers V to VI. Their numbers are low and they strongly express GFAP.
They have several short and straight processes as well as one to five very long (up to 1 mm)
processes that are usually straight, unbranched, and have numerous beads or varicosities
distributed about 10 µm apart. Unlike protoplasmic astrocytes, they are not organised into
well-defined spatial domains and their processes cross through domains of neighbouring
astrocytes. Their functions are unclear, arguably varicose-projection astrocytes contribute
to long-distance communication through cortical layers and even between grey and white
matter [44,46,49].
Fibrous astrocytes reside in white matter tracts; human astrocytes are much larger
than rodent ones. Fibrous astrocytes have a small round soma and straight nonbranched
processes. Their fibres overlap, but their bodies do not; they are equidistant from each
other. Their processes extend multiple finger-like cytoplasmic protrusions that are directed
into the perinodal spaces of the surrounding axons. In addition, fibrous astrocytes contact
blood vessels through their processes and endfeet, as do protoplasmic astrocytes [44,46,50].
While GFAP has proved to be a reliable marker of astrocytes in vitro, not all astrocytes
are immunopositive for GFAP in physiological conditions. Regional differences are also
reported with higher GFAP expression in hippocampal than in cortical, striatal or thalamic
astrocytes [51]. For reliable characterisation of astrocytic subtypes, immunohistochem-
ical morphometry must utilise additional markers, including cytosolic (such as S100β,
glutamine synthetase (GS), aldolase C, ALDH1L1) that allow a better visualisation of the
morphological profiles. Astroglia-specific fluorescent reporter mice (i.e., ALDH1L1-GFP),
astroglia-specific Cre lines or intraglial injection of fluorescent dyes can also improve
morphological characterization [52,53].
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Figure 2. Astrocyte morphologies in healthy and in Alzheimer’s disease brains. (A–C) Human iPSC-derived astroglial
progenitors transplanted into the mouse brain (RFP, red) integrate in the cortex and develop into interlaminar astrocytes
expressing GFAP (green). hN: human Nuclei stains the nuclei of human cells. Scale bar: 25 µm. (D–E) Close interaction
of both mouse and human astrocytes with β-amyloid plaques. GFAP-positive mouse or human astrocytes (red) around
β-amyloid plaques (6E10, green) in the cortex of an APP/PS1 mouse (D) and in the entorhinal cortex of an Alzheimer´s
disease patient brain (E). Scale bars: 10 µm.
2.3.2. Molecular Diversity and Functional Implications
The outbreak of new sequencing methodologies provides for remarkable expansion
of our knowledge of molecular diversity of astrocytes. Specialised subpopulations of
astrocytes have been recently identified across different brain regions by RNA sequencing
in astrocyte-specific reporter mice [54–56]. While all astrocytes are strongly enriched in
pan-glial gene signatures, each subpopulation shows a unique molecular profile across
regions. Distinct sub-populations of astrocytes also exhibit differences in morphology,
electrophysiology and calcium signalling [54,56]. These sub-populations also differ in
migratory and proliferative capacities, synaptic coverage and ability to support synap-
togenesis and neuronal growth and maturation [54–56], further corroborating astrocyte
diversity tailored to support specific brain regions. Even within a specific brain region,
such as cortex, astrocytes in different layers show distinct morphological features, gene sig-
natures, functional properties and cell-surface markers [57,58], indicating the high adaptive
potential of these cells.
Between and within-regional astrocyte diversity has recently been confirmed by single-
cell RNA sequencing and in situ analyses. Molecularly distinct astrocytic subtypes have
been described within the cortex, identifying superficial, mid and deep layer astrocyte
gene profiles in a layer patterning that differs from those of neurones [59]. Moreover,
up to five molecularly distinct astrocyte subtypes have been identified in mouse cortex
and hippocampus, each showing specific morphologies and distinct Ca2+ dynamics [60],
further highlighting region-dependent functional diversity.
Cells 2021, 10, 540 7 of 19
In summary, astrocyte gene expression varies between as well as within brain regions,
with astrocytes from each individual brain area showing a subtle and specific gene expres-
sion gradient. These molecular differences correlate with distinct morphological features
both having functional implications that are beginning to emerge.
3. Astrocytes in Alzheimer’s Disease
3.1. Major Roles of Astrocytes in Alzheimer´s Disease
Alzheimer’s disease (AD) is characterised by amyloid-β accumulation (β-amyloid or
senile plaques), formation of hyperphosphorylated tau neurofibrillary tangles, neuroin-
flammation, synaptic demise, neuronal death and brain dysfunction leading to severe
cognitive impairment. The amyloid hypothesis originally postulated a linearity of progres-
sion according to β-amyloid accumulation, which subsequently leaded to formation of
tangles and other pathological hallmarks [61]. More recent observations demonstrated that
such linear model needs to consider the contribution of different brain cells [62]. Evolution
of AD takes long time, with brain defences sustaining homeostasis for decades before
cognitive disability becomes apparent in advanced stages of the disease [62]. This cellular
defensive phase represents the biological equivalent of preclinical AD [63] and involves
complex circular and parallel pathways and poorly characterised homeostatic responses
associated with different types of brain cells [64].
The role for glial cells, and for astrocytes in particular, in neuropathology of many
neurodegenerative diseases is universally acknowledged [28,65]. The risk of AD is as-
sociated with genes mainly expressed by glial cells, either astrocytes, microglia and/or
oligodendrocytes [66]. Apolipoprotein E (APOE), a major genetic risk factor in Late-Onset
AD (LOAD), is mainly expressed in astrocytes in the healthy brain [67] and contributes
to accumulation of β-amyloid in the brain [68,69]. Other genes associated with AD such
as Clusterin (CLU) and Fermitin family member 2 (FERMT2) are similarly predominantly
expressed by astrocytes. Reactive astrogliosis is prominent in AD being an early event in
human patients and in animal models, possibly even preceding the formation of β-amyloid
plaques [70–72]. These data suggest a crucial role of astrocytes in the pathogenesis of AD.
Morphological studies in post-mortem AD patient brains demonstrated close interac-
tion between astrocytes and β-amyloid depositions [73] (Figure 2B). It is however unclear
how this close interaction translates into the disease progression. Astrocytes, when asso-
ciated with senile plaques, become reactive with morphological hypertrophy manifested
by thicker processes and increased expression of the intermediate filament proteins glial
fibrillary acidic protein (GFAP), vimentin, nestin and synemin [74]. Reactive astrocytes are
found in both human AD patient brains [75] and AD mice models (Figure 2B) [65,76,77].
Pathological signals inducing astrogliosis in AD can be associated with damaged cells; β-
amyloid by itself is a strong instigator of astrocyte reactivity. At molecular level, β-amyloid
induction of astrogliotic remodelling is mediated by Ca2+ release from the endoplasmic
reticulum; inhibition of the latter suppresses astrocytic reactivity [78]. In AD, astrocytes un-
dergo relatively mild isomorphic gliosis and astrocytic domains do not overlap, potentially
indicating a defensive nature of the astrocytic response. Indeed, inhibition of astrogliosis
exacerbates β-amyloid accumulation and histopathology in AD mice [79]. Reactive as-
trocytes in the vicinity of plaques display aberrant calcium dynamics [80,81]. Astrocyte
Ca2+ hyperactivity could promote the release of detrimental factors, alter neurone-glia
communication and impair synaptic transmission and plasticity [82,83] (Figure 3).
Besides substantial astroglial reactivity, atrophic astrocytes are also present in post-
mortem brains of AD patients [48,84] and mouse models of AD [65]. In particular, hu-
man AD brains are characterised by severe disruption or even complete disappearance
of interlaminar astrocytes [48]. Atrophic astrocytes are characterised by reduced volume
and thinner processes as revealed by morphometric analysis of cells immunolabelled with
antibodies against GFAP, S100β [85] and GS [86]. In the 3xTg-AD mice model, atrophic
astrocytes appear as early as 1-month age in the entorhinal cortex (EC) and the atrophy is
sustained after 12 months of age when β-amyloid plaques begin to appear [85]. Similar
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astroglial atrophy has been described in other models of AD including 5xTG-AD mice,
PDAPP-J20 transgenic mice and Swiss 3 [87–90]. Human astrocytes derived from induced
pluripotent stem cells (iPSC) from patients with both familial and sporadic forms of AD
also show atrophic phenotypes in vitro compared to control cells [91]. While atrophy
might lead to loss of astrocyte homeostatic functions and give rise to synaptic dysfunction,
increased excitability and/or damage of the BBB, (Figure 3) very little functional data are
available. Finally, neurodegenerative process may directly damage astrocytes resulting
in clasmatodendrosis, characterised by fragmentation and disappearance of distal fine
processes, along with swelling and vacuolation of the cell body [92] (Figure 3).
Astrocytes could be, in principle, involved in β-amyloid production as they upregulate
β-secretase 1 and the amyloid precursor protein (APP) in the diseased brain [82], however
no quantitative data points to astrocytes as the major source of β-amyloid. Astrocytes
more likely participate in β-amyloid clearance and elimination by different mechanisms.
Astrocytes express aquaporin 4 (AQP4) water channels in their vascular end-feet and play
an essential role in the glymphatic system implicated in the clearance of β-amyloid [42,43]
(Figure 3). They also produce β-amyloid degrading proteases that cleave the peptide into
smaller fragments. The metalloendopeptidases neprilysin (NEP), insulin-degrading en-
zyme (IDE), and endothelin-converting enzymes 1 and 2 (ECE1 and ECE2) are all expressed
in astrocytes and contribute to the degradation of monomeric β-amyloid species [93]. As-
trocytes also express matrix metalloproteinases MMP-2 and MMP-9 which degrade both
fibrillar and monomeric β-amyloid [93] (Figure 3). Clearance of β-amyloid can be medi-
ated by extracellular proteins APOE, ApoJ/Clusterin, α1-antichymotrypsin (ACT) and
α2-macroglobulin (α2-M), all produced by astrocytes (Figure 3); these proteins promote the
transport of β-amyloid across the BBB to the circulation either alone or in association with
LRP1 and VLDLR receptors [93]. Recent studies report that iPSC-derived human astrocytes
and mouse astrocytes expressing APOE4 are less efficient in clearing β-amyloid than those
expressing APOE3 [94,95]. In addition to β-amyloid clearance, APOE also regulates β-amyloid
seeding with APOE4 more potently affecting seed formation than APOE3. APOE affects plaque
size and neuritic dystrophy without having much influence on total amyloid load [96,97]. Ex-
pression of APOE4 also leads to degeneration of pericytes thus facilitating breakdown of the
BBB further contributing to cognitive impairment in APOE4 carriers [98].
In AD, reactive astrocytes interact with neurones, microglia and oligodendrocytes by
releasing feed-forward signals and contributing to the vicious cycle that leads to neurode-
generation. Of note, β-amyloid can activate the NF-κB pathway in astrocytes, which leads
to release of the complement protein C3 (Figure 3). The C3 binding to the microglial
receptor C3aR alters β-amyloid phagocytosis while the C3 binding to the neuronal receptor
C3aR disrupts dendritic morphology and network function, both effects contributing to
AD pathogenesis [99]. Both NF-κB and C3 cascades are activated in human AD brain and
in AD mouse models [100,101]. Microglia can also activate astrocytes by secreting specific
cytokines (IL-1α, TNFα, and C1q) [101]. This type of reactive astrocytes upregulate classical
complement cascade genes including C3 and lose ability to promote synapse formation
and function, and to phagocytose synapses and myelin debris [101]. About 60% of the
astrocytes in the prefrontal cortex of AD patients are C3-expressing astrocytes [101] and
could contribute to neuronal damage; although further analyses are needed for confirma-
tion. In AD, reactive astrocytes participate in shifting the excitation-inhibition balance
through secretions of GABA. In the healthy brain, astrocytes do not contribute much to
GABA production, however, in AD GABA starts to be synthesised by astrocytes through
putrescine-MAO-B pathway [102]. In this way, reactive astrocytes start to secrete GABA
thus increasing inhibition, likely to be a defensive response against neuronal hyperexcitabil-
ity that seems to be a universal result of AD progression [103,104]. Increase in MAO-B
expression in astrocytes, which accompanies AD, also results in a hyperproduction of
hydrogen peroxide that may instigate neuronal damage and death [105].
Cells 2021, 10, 540 9 of 19
Figure 3. Contribution of astrocytes to Alzheimer´s disease. During the course of AD, astrocytes interact with neurones,
microglia and other CNS cells by releasing feed-forward signals and contributing to the vicious cycle leading to neurode-
generation. While reactive astrocytes potentially have both protective and detrimental functions during the course of AD,
atrophic astrocytes might lose their homeostatic functions. Astrocyte contribution to β-amyloid degradation and clearance
will also influence AD progression.
Metabolic deficits [106] and mitochondrial dysfunction also contribute to AD pro-
gression [107,108]. Extensive transcriptomics and proteomics studies revealed deficient
mitochondrial bioenergetics in the AD brains [109–111]. Mitochondrial genes are altered
in astrocytes from AD human brains as we discussed in detail in next section [112,113].
Exposure of mouse astrocytes to β-amyloid up-regulates superoxide dismutase thus in-
creasing oxidative stress [114]; while continuous infusion of β-amyloid into mice brains
results in substantial increase in production of hydrogen peroxide [115]. H2O2 over-
producing astrocytes have been recently detected in the brains of AD model mice [105].
The β-amyloid/APP present in the mitochondrial inner membrane impairs the activity
of Complex IV [116]. The toxic effect of β-amyloid on astrocytes is manifested by mi-
tochondrial depolarisation with subsequent loss of Ca2+ homeostasis [117]. Astrocytic
mitochondria are concentrated near the sites of homeostatic transport [118,119] providing
energy of Na+/K+-ATPase that in turn drives accumulation of neurotransmitters, of which
glutamate is the most prominent; deficits in ATP supply may affect glutamate clearance and
promote excitotoxicity. Mitochondrial dynamics and function is also impaired in human
astrocytes bearing APOE4 allele [120]. Another fundamental neuroprotective capability
of astrocytes is linked to mitochondrial quality control and mitochondrial degradation.
Astrocytes assist neuronal mitochondrial recycling through transmitophagy, when crippled
neuronal mitochondria are transported to astrocytes where they undergo degradation [121].
Moreover, there are some indications that astrocytic mitochondria can be shuttled into
neurones and assist to neuronal bioenergetics; in particular these processes seem to support
neuroprotection after stroke [122]. Neuronal-astrocytic transmitophagy has been found
to exert neuroprotection in the context of Parkinson disease [123]; whether this process
contributes to the AD remains an exciting and albeit unanswered question.
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Astrocytes potentially contribute to neuronal damage in other human neurodegen-
erative diseases such as Parkinson’s disease [124–126], Huntington’s disease [127,128],
multiple sclerosis [129,130] and amyotrophic lateral sclerosis [131], indicating a direct
contribution of these cells to a general programme of neurodegeneration. Most probably,
astrocyte states and phenotypes differ among diseases, and even at different stages of a
specific disease; further analyses are needed to dissect specific molecular pathways related
to specific disease stages.
At the same time, astrocytes can exert neuroprotection at different stages of AD.
Both astrogliosis and microgliosis in response to β-amyloid increase glial secretion of
transforming growth factor β (TGF-β) (Figure 3). TGF-β protects neurones from β-amyloid
toxicity and enhances β-amyloid clearance by microglia [88,99]. Moreover, astrocytes sur-
rounding β-amyloid plaques demonstrate phagocytic activity and are able to phagocytose
neuritic dystrophies in both mouse models and AD patients’ brains, further suggesting
beneficial roles of astrocytes in AD [132]).
These data show that astrocytes actively contribute to the pathogenesis of AD. At the
same time many questions remain to be addressed. What astroglial states/phenotypes
are found at different stages of AD? How do astrocyte states/phenotypes differ between
brain regions, which are known to have different vulnerability to AD? How do astrocytes
crosstalk with other brain cells? Are they able to promote neurodegeneration? How do
AD risk genes modulate astroglia responses in AD? New methodologies such as RNA
sequencing and spatial transcriptomics in combination with the use of human iPSC-derived
models and CRISPR-based studies are providing deeper understanding into how astrocytes
evolve during the course of AD.
3.2. Astrocyte Genes and Altered Molecular Pathways in AD
RNA sequencing approaches are providing novel information about astrocyte states
and soon we will be able to relate these states to different stages of AD. RNA sequencing
analyses on acutely isolated mouse astrocytes revealed increased expression of inflamma-
tory response genes (Cst7, Ccl4, Il1b, Clec7a, Tyrobp) and reduced expression of neuronal
support genes (Hes5) and cholesterol biosynthesis genes (Tm7sf2, Cyp51, Mvd) in astro-
cytes from AD model mice (APPswe/PS1dE9) compared to healthy controls [133] (Table 1).
When looking at specific genes, mouse astrocytes upregulate Gfap, Bcl3, Serpina3n, Cyb5r2,
Chil4, Bdkrb2, Rnase4 and the complement cascade genes C4a, C4b in AD model mice
(PS2APP and APP/PS1) compared to control mice [134,135] (Table 1). In AD and healthy
human post-mortem brains, transcriptional analyses of isolated astrocytes from different
regions revealed differential expression of genes in pathways regulating cytoskeleton
(MYO6, KIF21A, ACTNB), cell signalling (IGF1R, PIK3R1, MAP3K12), tight junctions (GJC1,
ZO1, TJAP1) [136], and lipid metabolism (ACOT1, ACOT2) [137], as well as dysregulation
of mitochondria-related genes (TRMT61B, FASTKD2, NDUFA4L2) and immune response
genes (CLU, C3, CD74) [112] (Table 1). Overall, these data support astrocyte-specific con-
tributions to AD mainly related to lipid metabolism, cholesterol biosynthesis, immune
responses, and neuronal support, highlighting the importance of astrocyte activity in the
neurodegenerative process.
While RNA sequencing of pooled astrocytes robustly corroborates the contribution
of these cells to AD pathophysiology, it only captures expression of genes in grouped
cells thus yielding population averages. Such transcriptome analyses can be affected by
alterations in cell type composition of diseased vs. control samples and is unable to detect
specific cell states, or changes in gene expression that occur in cell subsets. Therefore,
single-cell or single-nuclei RNA sequencing are providing deeper insight in how cellular
states evolve during AD progression.
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Table 1. Summary of differentially expressed genes (DEGs) and molecular pathways based on RNA sequencing analysis of
astrocytes in Alzheimer’s disease. DEGs are shown comparing AD vs. control mice and AD patient vs. human healthy
brain samples. Upregulated genes are shown in red, downregulated genes in blue and dysregulated genes in green.
Species Brain Region RNA-SeqTechnique
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Method DEGs Pathways Refs
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Single-nucleus RNA sequencing of mouse astrocytes identified sub-populations of
GFAP-low and GFAP-high astrocytes in both WT and AD mice (5xFAD); in addition,
a unique cluster of disease-associated astrocytes (DAA) was detected in the AD mice [138].
The DAA cluster was enriched in Gfap, Serpina3n, Ctsb, Apoe and Clu among other genes
(Table 1). While Apoe and Clu are known AD risk genes involved in amyloid processing,
Ctsb encodes a lysosomal protease, Cathepsin B, linked to proteolytic processing of the
amyloid precursor protein (APP), and Serpina3n encodes a protease inhibitor associated
with increased β-amyloid accumulation. Serpina3n has also been identified in astrocytes
from other AD model mice [134,135]; thus becoming a prime candidate for future in-
vestigations. Most of the detrimental astrocytic signature genes described in previous
studies [101] are expressed by DAAs. Moreover, there are up to 18 genes shared by DAAs
and disease-associated microglia [142], including Apoe, Ctsb, Ctsd and Ctsl, all encoding
proteins involved in AD pathogenesis suggesting a general transcriptional program shared
across cell types in AD. DAAs appear at early stages of AD and become more abundant
as disease progresses suggesting that they not only respond to disease but also modulate
disease course. Similar “pathological” astrocytes also emerge in aged WT mice and in
ageing human brains [138], suggesting such molecular signatures are at least partially
linked to age-related factors.
Single-nucleus RNA sequencing performed in parallel in both human control and
AD brain samples and WT and AD mouse models (5xFAD) revealed remarkably different
Cells 2021, 10, 540 13 of 19
signatures between human and mice in astrocytes, as well as in microglia and oligodendro-
cytes [139]. While in AD mice astrocytes upregulate Gfap and C4b, in human AD brains
astrocytes upregulate genes involved in extracellular matrix pathways including NCAN
and COL5A3 and downregulate genes involved in lipid and oxidative metabolism includ-
ing FABP5, HILPDA and SOD2 (Table 1) [139]. These data highlight the importance of
analysing human samples to dissect molecular pathways involved in AD; direct translation
from animal models could often be misleading.
Single-nucleus RNA sequencing of entorhinal cortex from human healthy and AD
brains (n = 6 per group) revealed changes in specific astrocyte subpopulations [113].
While the AD astrocyte subcluster called a1 in this study upregulated genes involved
in ribosomal, mitochondrial, neurone differentiation and heat shock responses, the AD
astrocyte subcluster called a2 downregulated these processes and upregulated genes in-
volved in transforming growth factor β (TGF-β) signalling and immune responses (Table 1).
Upregulation of C3 was also observed in AD astrocytes from the a2 subcluster in agreement
with previous bulk RNA-seq analyses [112]. When analysing the expression of 1000 GWAS
candidate genes for AD and AD-related traits, ADAMTS18, KCNN3 and BIN1 were found
upregulated, whereas RGS20, FRMD4A and APOE were downregulated in AD astrocytes
(Table 1). APOE was downregulated in both a1 and a2 subclusters, in agreement with
previous observations in human iPSC-derived astrocytes [94], while it was upregulated in
microglial AD subcluster. The transcription factor TFEB, a master regulator of lysosomal
function, is upregulated in AD astrocytes; TFEB was found to drive a network of ten AD
GWAS genes (BIN1, CLDN11, POLN, STK32B, EDIL3, AKAP12, HECW1, WDR5, LEMD2,
and DLC1). All these genes were dysregulated in AD astrocytes, suggesting that this master
regulator controls the transition of astrocytes to a specific state identified by authors as
“diseased” [113]. Single-nucleus sequencing was also performed in the prefrontal cortex
of a bigger cohort of human control and AD brains (n = 24 per group) and confirmed
APOE downregulation in AD astrocytes along with upregulation in microglia [140]. Sub-
clustering of astrocyte nuclei revealed four subpopulations of cells with one subcluster
called Ast1 enriched with AD cells that upregulated GLUL and the AD risk gene CLU [140]
(Table 1), previously found upregulated in reactive astrocytes in response to neurodegen-
eration [143]. Recent single-nucleus sequencing of the entorhinal cortex and the superior
frontal gyrus from human healthy brains (n = 3), early (n = 4) and advanced (n = 3) stages
of AD also revealed an astrocyte subpopulation expressing higher levels of GFAP, called
GFAP-high [141]. GFAP-high astrocytes upregulate CD44 and TNC, both involved in
interactions with the extracellular matrix; as well as HSPB1 and HSP90AA1, chaperones
involved in proteostasis. Interestingly, GFAP-high astrocytes downregulated genes in-
volved in glutamate and GABA homeostasis (SLC1A2, SLC1A3, GLUL and SLC6A11) and
synaptic adhesion/maintenance (NRXN1, CADM2, PTN and GPC5), indicating they may
have compromised homeostatic function [141] (Table 1).
Overall, these studies provide complementary snapshots of astrocytic responses to
pathology in the AD brain. Although there is still an acute need for more in-depth RNA
sequencing analyses combined with large-scale meta-analyses on astrocyte transcriptomic
datasets [144], the identification of genes and transcription factors that orchestrate the
conversion of control to AD-associated astrocytes can already pinpoint specific molecular
processes. In the coming years, integration of the most advanced sequencing technolo-
gies i.e., spatial transcriptomics [145,146] with multi-omics approaches i.e., epigenomics,
proteomics and metabolomics [147–149] will allow validation of the present findings and
provide specific mechanisms for therapeutic intervention.
4. Conclusions and Future Directions
Astrocytes have multiple functions in the brain and are essential for protection of neu-
rones and maintenance of homoeostasis. However, under different pathological conditions
including AD, they acquire diverse states, associated with either gain or loss of function con-
tributing to neuroinflammation and neurodegeneration (Figure 3). A complete description
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of these cellular states, including multi-omics approaches combined with morphological
and functional analyses, will advance understanding of how astrocytes evolve in pathology
and in the near future, we may be able to relate different astroglial states to specific stages
of AD, which might lead to novel biomarkers and targets for therapeutic intervention.
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